Why Innovent Biologics and SanegeneBio believe IBI3016 could change hypertension treatment

Innovent Biologics (HKEX: 01801) and Sanegene Bio USA Inc. have jointly unveiled promising Phase 1 data for IBI3016, a GalNAc-conjugated RNA interference-based therapeutic designed to treat hypertension through durable suppression of angiotensinogen (AGT) mRNA. The first-in-human trial results were presented at the American Heart Association’s (AHA) 2025 Scientific Sessions, with evidence showing significant and sustained AGT inhibition and preliminary antihypertensive effects following a single subcutaneous injection.

The experimental therapy, also referred to by Sanegene Bio USA Inc.’s internal code SGB-3908, is being developed as a potential biannual injection to replace daily oral antihypertensives. The trial enrolled 40 healthy and mildly hypertensive Chinese adults across five dose cohorts. The randomized, double-blind, placebo-controlled study assessed safety, tolerability, pharmacokinetics, and pharmacodynamics of IBI3016 over a six-month period.

What are the key findings from the Phase 1 trial of IBI3016 presented at AHA 2025?

The clinical study (NCT06501586 / CTR20242500) included 40 participants between the ages of 24 and 54, with a mean body mass index of 25.2 kg/m² and average baseline ambulatory blood pressure of 122/74 mmHg. Each dose cohort followed a 6:2 randomization between IBI3016 and placebo.

Following a single dose, IBI3016 delivered maximum AGT suppression of over 95 percent in higher dose groups, with suppression levels maintained above 90 percent through three months. At the six-month mark, AGT levels remained suppressed between 85.9 percent and 96.4 percent across cohorts.

In terms of antihypertensive effect, all treated cohorts demonstrated reductions in both systolic and diastolic blood pressure. The most pronounced reductions in 24-hour mean systolic and diastolic pressures were seen in the highest dose group, which recorded decreases of −16.7 mmHg and −14.7 mmHg respectively during daytime hours. This compared favorably to the placebo group, which saw only −3.2 mmHg and −5.7 mmHg reductions. Similar trends were observed during nighttime readings, reinforcing the early efficacy profile of IBI3016.

No severe adverse events or serious complications were observed during the trial. All reported adverse events were classified as mild to moderate and were reversible. Importantly, no hypotension cases were recorded across any dose group, supporting the favorable safety profile of the agent.

Why are RNAi therapies like IBI3016 considered promising for chronic hypertension?

Despite the availability of effective oral treatments for hypertension, long-term control remains elusive for a majority of patients due to adherence issues, biological escape mechanisms, and a lack of early symptoms. Hypertension affects approximately 1.4 billion individuals worldwide, yet less than 20 percent of them achieve optimal blood pressure control, according to global public health estimates.

RNA interference-based therapies offer a fundamentally different approach by targeting the genetic drivers of disease. IBI3016 is designed to inhibit the production of AGT in liver cells through precise RNA interference, leading to a downstream suppression of the entire renin-angiotensin-aldosterone system. This upstream inhibition mechanism not only reduces blood pressure but may also address the problem of aldosterone escape, a phenomenon that blunts the long-term effectiveness of conventional antihypertensive drugs.

Innovent Biologics and Sanegene Bio USA Inc. are leveraging GalNAc conjugate technology to deliver the siRNA directly to hepatocytes, enhancing both specificity and durability. This delivery strategy allows for extended dosing intervals, potentially reducing the burden of daily medication and improving patient compliance. With hypertension being largely asymptomatic in its early stages, a biannual injection model could help reduce global cardiovascular morbidity.

How are Innovent Biologics and Sanegene Bio USA Inc. positioning IBI3016 in the broader therapeutic landscape?

For Innovent Biologics, the advancement of IBI3016 reflects a strategic expansion beyond its established portfolio in oncology, autoimmune disorders, and ophthalmology. The Chinese biopharmaceutical company has launched 16 products in the market and currently has two new drug applications under regulatory review. With over 15 molecules in early-stage development and four in pivotal trials, Innovent Biologics is increasingly focused on building leadership in chronic disease management.

Sanegene Bio USA Inc., established in 2021 with operations in Boston, Shanghai, and Suzhou, has centered its pipeline on RNAi therapies addressing cardiometabolic, autoimmune, and obesity-related conditions. The company is backed by investors who support its LEAD™ tissue-selective delivery platform, which underpins the design of IBI3016 and several other pipeline candidates.

Executives from both companies expressed strong optimism regarding the future of IBI3016. Dr. Lei Qian, Chief R&D Officer of General Biomedicine at Innovent Biologics, described the Phase 1 data as validating the long-acting potential of siRNA therapeutics in hypertension. He added that the collaboration with Sanegene Bio USA Inc. would now focus on scaling up clinical efforts with scientific rigor and high operational quality.

Dr. Yuyan Jin, Senior Vice President of Clinical and Non-Clinical Development at Sanegene Bio USA Inc., echoed this sentiment, citing the significant unmet need in hypertension and the challenges posed by traditional oral drugs. She emphasized that IBI3016 could offer a viable alternative by addressing key barriers such as poor adherence and escape mechanisms.

What are the regulatory and development hurdles before IBI3016 enters late-stage trials?

Although the results from the first-in-human trial are promising, IBI3016 remains at an early phase of development. Regulatory advancement will depend on the successful initiation and completion of Phase 2 studies that include more diverse patient populations and longer follow-up periods. Such studies will also need to demonstrate reproducibility of blood pressure control in real-world settings, alongside comprehensive safety monitoring.

Another consideration is scalability and cost-effectiveness. While GalNAc-conjugated siRNA drugs have been commercialized in rare diseases, their application to widespread conditions like hypertension poses logistical and economic challenges. Manufacturing capacity, distribution models, and health system affordability will play critical roles in determining the adoption of RNAi-based therapies in primary care settings.

Nonetheless, both companies appear committed to navigating these hurdles with a long-term strategy that prioritizes clinical quality, patient benefit, and platform scalability.

How are investors and market participants responding to this early RNAi success in hypertension?

Innovent Biologics remains one of the most closely watched biopharmaceutical players listed on the Hong Kong Stock Exchange. Institutional sentiment has generally been positive, buoyed by consistent product launches and a pipeline that spans high-growth therapeutic categories. The company’s collaborations with Eli Lilly, Sanofi, Incyte, and LG Chem have further strengthened its profile among investors.

Analysts believe that the entry into cardiometabolic diseases could diversify Innovent Biologics’ revenue streams and reduce over-reliance on oncology, where competition is intensifying. While IBI3016 may take several years to reach regulatory approval, its mechanism and long-term potential could position it as a first-in-class solution if subsequent trials succeed.

Sanegene Bio USA Inc., although privately held, has also garnered increasing attention for its differentiated approach to RNAi delivery. The success of IBI3016 could boost confidence in the company’s broader pipeline and help secure future funding rounds or strategic partnerships.

What is the future outlook for IBI3016 and the use of RNAi in chronic disease?

The successful presentation of IBI3016 at AHA 2025 marks a significant milestone in the application of RNAi technology to common chronic conditions. Until now, most RNAi drugs have been limited to rare or orphan indications. A transition to large-scale chronic diseases like hypertension signals a broadening of the therapeutic footprint for gene-silencing platforms.

Innovent Biologics and Sanegene Bio USA Inc. have indicated that further trials will begin soon, although specifics regarding geographies, endpoints, or anticipated enrollment numbers have not been disclosed. The development plan is expected to include larger Phase 2 trials involving treatment-resistant or comorbid patients, with eventual ambitions to secure approvals in China, the United States, and other major markets.

The broader implication of IBI3016 is a potential paradigm shift in hypertension care, from daily pill regimens to long-acting injectable therapies that target disease mechanisms at the genetic level. If the early promise holds, this approach could redefine patient expectations and treatment standards in primary care cardiology.

Key takeaways from Innovent Biologics and Sanegene Bio USA Inc.’s Phase 1 IBI3016 trial

• IBI3016 achieved sustained AGT suppression of over 90 percent across all dose cohorts, with reductions above 95 percent in higher-dose groups and durability extending up to six months after a single subcutaneous dose.
• Ambulatory blood pressure reductions were observed in all treatment groups, with the highest-dose cohort showing decreases of approximately −16.7 mmHg systolic and −14.7 mmHg diastolic, outperforming placebo effects.
• No severe adverse events, serious complications, or hypotension cases were reported, and all observed side effects were mild to moderate and resolved without intervention.
• IBI3016 is being developed as a biannual injectable to address poor adherence associated with daily oral antihypertensive medications and to reduce aldosterone escape through upstream RAAS pathway inhibition.
• Innovent Biologics and Sanegene Bio USA Inc. plan to advance the therapy into the next stage of clinical development, with larger Phase 2 studies expected to follow.
• Investor sentiment toward Innovent Biologics remains positive as the company expands further into chronic cardiometabolic conditions, diversifying its revenue streams beyond oncology.
• IBI3016 may represent one of the first applications of RNA interference technology in widespread chronic diseases, signaling a shift toward long-acting, gene-targeted systemic therapies in hypertension care.